Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pancuronium Bromide

FDA-approved product (injectable, injection), marketed as Pancuronium Bromide, Pavulon.

Registered studies
7
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Pancuronium Bromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Pancuronium Bromide. Its therapeutic class is shown instead.

WHO therapeutic group
Other quaternary ammonium compounds
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli22.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

7registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pancuronium Bromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pancuronium Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Erector Spinae Plane Block in Congenital Heart Disease Patients

    NCT04158024 · start 2025-11

    Registered record
    Registry ID
    NCT04158024
    Conditions
    Congenital Heart Disease in Children; Neurologic Complication
    Interventions
    Erector Spinae Plane Block
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-11
    Completion
    2026-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Heart Disease in Children; Neurologic Complication
    InterventionErector Spinae Plane Block
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery

    NCT03630796 · start 2018-08-20

    Registered record
    Registry ID
    NCT03630796
    Conditions
    Congenital Heart Defects
    Interventions
    Sevoflurane; TIVA
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-08-20
    Completion
    2019-12
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Heart Defects
    InterventionSevoflurane; TIVA
    PhasePhase 4
    Registry statusUnknown

  • Effects of Dexmedetomidine on Cognitive Outcome and Brain Injury Markers

    NCT03585452 · start 2018-08-01

    Registered record
    Registry ID
    NCT03585452
    Conditions
    Cognitive Dysfunction
    Interventions
    Dexmedetomidine Infusion; Propofol based general anesthesia
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-08-01
    Completion
    2019-03-31
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognitive Dysfunction
    InterventionDexmedetomidine Infusion; Propofol based general anesthesia
    PhaseNot applicable
    Registry statusCompleted

  • FETO With Long Tail Balloon for a Treatment of Severe CDH

    NCT03431792 · start 2017-08-30

    Registered record
    Registry ID
    NCT03431792
    Conditions
    Severe Congenital Diaphragmatic Hernia
    Interventions
    Long Tail Balloon
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-08-30
    Completion
    2021-08-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Congenital Diaphragmatic Hernia
    InterventionLong Tail Balloon
    PhaseNot applicable
    Registry statusUnknown

  • Fetal Cystoscopy Versus Vesico-amniotic Shunting in Severe Lower Urinary Tract Obstructions

    NCT01552824 · start 2015-06

    Registered record
    Registry ID
    NCT01552824
    Conditions
    Lower Urinary Tract Obstructive Syndrome
    Interventions
    CYSTO; Vesico-amniotic shunt
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-06
    Completion
    2018-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLower Urinary Tract Obstructive Syndrome
    InterventionCYSTO; Vesico-amniotic shunt
    PhasePhase 2
    Registry statusUnknown

  • The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)

    NCT03882788 · start 2013-04-22

    Registered record
    Registry ID
    NCT03882788
    Conditions
    Anesthesia; Adverse Effect; Congenital Heart Disease; Neurodevelopmental Disorders
    Interventions
    Isoflurane; Fentanyl (high dose); Fentanyl (low dose)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-04-22
    Completion
    2020-11-19
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnesthesia; Adverse Effect; Congenital Heart Disease; Neurodevelopmental Disorders
    InterventionIsoflurane; Fentanyl (high dose); Fentanyl (low dose)
    PhaseNot applicable
    Registry statusCompleted

  • Rapid Infusion of Cold Normal Saline During CPR for Patients With Out-of-hospital Cardiac Arrest

    NCT01173393 · start 2010-07

    Registered record
    Registry ID
    NCT01173393
    Conditions
    Out-of-hospital Cardiac Arrest
    Interventions
    PARAMEDIC COOLING
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07
    Completion
    2014-12
    Enrolment
    1,220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOut-of-hospital Cardiac Arrest
    InterventionPARAMEDIC COOLING
    PhasePhase 3
    Registry statusCompleted